The UK’s life sciences sector will receive £279 million from drugs giant Eli Lilly, to invest in developing new medicines and ways to deliver treatment. “The long-term benefits of these drugs could be ...

The U.S. Food and Drug Administration (FDA) is rethinking its decision to remove popular weight-loss and diabetes drugs from ...

Hims stock has rallied almost 22% this week on enthusiasm after the FDA said it will allow compounded versions of Lilly's ...

In response to a lawsuit, the FDA has said that it will reevaluate its previous decision to remove tirzepatide from its ...

Eli Lilly’s senior VP of information and R&D IT, Ramesh Durvasula, said Lilly will use AI and tech to transform the company.

Eighty states, cities, counties, school boards and unions have joined litigation in a New Jersey district court against the three major pharmacy middlemen.

Charities in Greater Manchester where a trial will test the effect of weight loss jabs on employment have said obesity is ...

Eli Lilly's valuation could look much more modest in the future, as its earnings should continue to grow at a high rate.

Eli Lilly has announced a strategic collaboration with UK government departments to address population health challenges, ...

Eli Lilly (NYSE: LLY) has partnered with the UK government, investing £279 million ($340 million) to address public health ...

The UK government starts a trial offering weight loss drug Mounjaro to unemployed obese individuals to improve health and ...

Eli Lilly's weight-loss drug is no longer on the Food and Drug Administration's drug shortage list. Compounding pharmacies say this will limit patient access.